INDICATORS ON AZD3965 YOU SHOULD KNOW

Hepatic impairment No dose adjustment is needed in sufferers with moderate or reasonable (Little one-Pugh A or B) hepatic impairment (see area 5.two). Publicity to midostaurin and its Lively metabolite CGP62221 is considerably decreased in clients with significant hepatic impairment than that in sufferers with typical hepatic operate (see segment 5